JP2020519675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519675A5 JP2020519675A5 JP2019563246A JP2019563246A JP2020519675A5 JP 2020519675 A5 JP2020519675 A5 JP 2020519675A5 JP 2019563246 A JP2019563246 A JP 2019563246A JP 2019563246 A JP2019563246 A JP 2019563246A JP 2020519675 A5 JP2020519675 A5 JP 2020519675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- immunoconjugate
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 76
- 229940127121 immunoconjugate Drugs 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 20
- 102100035139 Folate receptor alpha Human genes 0.000 claims 14
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 14
- 238000003364 immunohistochemistry Methods 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- 150000003431 steroids Chemical class 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000002628 peritoneum cancer Diseases 0.000 claims 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 5
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 5
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 5
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 230000002611 ovarian Effects 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 3
- 239000003889 eye drop Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000009095 third-line therapy Methods 0.000 claims 2
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 229960000520 diphenhydramine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000009093 first-line therapy Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- SVVGCFZPFZGWRG-OTKBOCOUSA-N maytansinoid dm4 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)C(C)(C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 SVVGCFZPFZGWRG-OTKBOCOUSA-N 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000009094 second-line therapy Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023096307A JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506940P | 2017-05-16 | 2017-05-16 | |
| US62/506,940 | 2017-05-16 | ||
| US201762560462P | 2017-09-19 | 2017-09-19 | |
| US62/560,462 | 2017-09-19 | ||
| US201862647008P | 2018-03-23 | 2018-03-23 | |
| US62/647,008 | 2018-03-23 | ||
| PCT/US2018/032692 WO2018213260A1 (en) | 2017-05-16 | 2018-05-15 | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096307A Division JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519675A JP2020519675A (ja) | 2020-07-02 |
| JP2020519675A5 true JP2020519675A5 (enExample) | 2021-06-17 |
| JPWO2018213260A5 JPWO2018213260A5 (enExample) | 2022-05-18 |
Family
ID=64269828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563246A Pending JP2020519675A (ja) | 2017-05-16 | 2018-05-15 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ−１抗体の組み合わせ |
| JP2023096307A Pending JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096307A Pending JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20180333503A1 (enExample) |
| EP (1) | EP3625262A4 (enExample) |
| JP (2) | JP2020519675A (enExample) |
| KR (1) | KR20200006546A (enExample) |
| CN (2) | CN118078987A (enExample) |
| AU (1) | AU2018269173A1 (enExample) |
| BR (1) | BR112019023909A8 (enExample) |
| CA (1) | CA3063893A1 (enExample) |
| IL (1) | IL314823A (enExample) |
| MX (1) | MX2019013753A (enExample) |
| RU (1) | RU2019141270A (enExample) |
| TW (3) | TW202440170A (enExample) |
| WO (1) | WO2018213260A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| CA3182262A1 (en) | 2011-04-01 | 2012-10-04 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
| BR112020016469A2 (pt) | 2018-03-13 | 2020-12-15 | Phanes Therapeutics, Inc. | Anticorpos do receptor anti-folato 1 e seus usos |
| WO2020060944A1 (en) * | 2018-09-17 | 2020-03-26 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
| KR20220008253A (ko) * | 2019-01-03 | 2022-01-20 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물 |
| EP4326770A1 (en) | 2021-04-23 | 2024-02-28 | King's College London | Composition comprising an ige antibody |
| TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
| CN115960269A (zh) * | 2023-01-30 | 2023-04-14 | 上海甲贝医药科技有限公司 | 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法 |
| CN120919340A (zh) * | 2024-05-09 | 2025-11-11 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 |
| CN118684782A (zh) * | 2024-07-17 | 2024-09-24 | 武汉科技大学 | 一种muc16和folr1双靶点嵌合抗原受体dcar-16-r1及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582150A (en) * | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| KR20170085143A (ko) * | 2010-02-24 | 2017-07-21 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| EP2904011B1 (en) * | 2012-10-02 | 2017-08-23 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| UA119541C2 (uk) * | 2013-10-08 | 2019-07-10 | Іммуноджен, Інк. | Застосування імунокон'югата, який зв'язується з folr1 |
| WO2015149018A1 (en) * | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| SG11201704056XA (en) * | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| EP3233918A1 (en) * | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| JP6880006B2 (ja) * | 2015-09-17 | 2021-06-02 | イミュノジェン， インコーポレイテッド | 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ |
-
2018
- 2018-05-15 MX MX2019013753A patent/MX2019013753A/es unknown
- 2018-05-15 IL IL314823A patent/IL314823A/en unknown
- 2018-05-15 JP JP2019563246A patent/JP2020519675A/ja active Pending
- 2018-05-15 BR BR112019023909A patent/BR112019023909A8/pt unknown
- 2018-05-15 RU RU2019141270A patent/RU2019141270A/ru unknown
- 2018-05-15 EP EP18802195.0A patent/EP3625262A4/en not_active Withdrawn
- 2018-05-15 AU AU2018269173A patent/AU2018269173A1/en not_active Abandoned
- 2018-05-15 US US15/979,989 patent/US20180333503A1/en not_active Abandoned
- 2018-05-15 CA CA3063893A patent/CA3063893A1/en active Pending
- 2018-05-15 CN CN202410214686.8A patent/CN118078987A/zh active Pending
- 2018-05-15 KR KR1020197034686A patent/KR20200006546A/ko not_active Ceased
- 2018-05-15 CN CN201880032356.XA patent/CN110799535A/zh active Pending
- 2018-05-15 WO PCT/US2018/032692 patent/WO2018213260A1/en not_active Ceased
- 2018-05-16 TW TW113100663A patent/TW202440170A/zh unknown
- 2018-05-16 TW TW107116641A patent/TW201900221A/zh unknown
- 2018-05-16 TW TW111134010A patent/TW202322853A/zh unknown
-
2021
- 2021-07-21 US US17/382,286 patent/US20220160889A1/en not_active Abandoned
-
2023
- 2023-06-12 JP JP2023096307A patent/JP2023113921A/ja active Pending
- 2023-10-18 US US18/489,292 patent/US20240299571A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519675A5 (enExample) | ||
| RU2019141270A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| JP6800853B2 (ja) | 抗ｃ１０ｏｒｆ５４抗体およびその使用 | |
| JP2019031568A5 (enExample) | ||
| TWI795347B (zh) | 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌 | |
| JP2025129187A5 (enExample) | ||
| JP2018527383A5 (enExample) | ||
| JP2019500020A5 (enExample) | ||
| BR112020016986A2 (pt) | formulações de anticorpo contra b7-h4 | |
| US12324841B2 (en) | Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate | |
| JP2020502271A5 (enExample) | ||
| CA3091217A1 (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| US20250154250A1 (en) | Ceacam5 adc-anti-pd1/pd-l1 combination therapy | |
| BR112020013144A2 (pt) | Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer | |
| CA3118542A1 (en) | Cdcp1-targeted therapies | |
| TW202228788A (zh) | 以結合191p4d12蛋白之抗體藥物結合物（adc）治療癌症之方法 | |
| JPWO2018213260A5 (enExample) | ||
| EP4561623A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| AU2022318734A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| RU2022129967A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| EP4427763A1 (en) | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies | |
| WO2024213081A1 (zh) | 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途 | |
| WO2025064741A1 (en) | Treating locally advanced or metastatic urothelial cancer with anti-191p4d12 antibody drug conjugates in combination with pembrolizumab | |
| TW202539742A (zh) | 抗體藥物偶聯物和抗ｖｅｇｆ抗體的聯合應用 | |
| KR20250169564A (ko) | 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정 |